Seonaid Nolan1, Kanna Hayashi2, M-J Milloy2, Thomas Kerr2, Huiru Dong3, Viviane Dias Lima2, Leslie Lappalainen3, Julio Montaner2, Evan Wood2. 1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Electronic address: seonaidn@gmail.com. 2. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. 3. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6.
Abstract
BACKGROUND: Methadone maintenance therapy (MMT) is among the most effective treatment modalities available for the management of opioid use disorder. However, the effect of MMT on mortality, and optimal strategies for delivering methadone are less clear. This study sought to estimate the effect of low-threshold MMT and its association with all-cause mortality among persons who inject drugs (PWID) in a setting where methadone is widely available through primary care physicians and community pharmacies at no cost through the setting's universal medical insurance plan. METHODS: Between May, 1996 and December, 2011 data were collected as part of two prospective cohort studies of PWID in Vancouver, Canada, and were linked to the provincial vital statistics database to ascertain rates and causes of death. The association of MMT with all-cause mortality was estimated using multivariable extended Cox regression with time-dependent variables. RESULTS: Of 2335 PWID providing 15027 person-years of observation, 511 deaths were observed for a mortality rate of 3.4 (95% Confidence Interval [CI]: 3.1-3.7) deaths per 100 person-years. After adjusting for potential confounders including age and HIV seropositivity, MMT enrolment was found to be associated with lower mortality (adjusted hazard ratio [AHR]=0.73, 95% CI: 0.61-0.88). CONCLUSIONS: While observed all-cause mortality rates among PWID in this setting were high, participation in low-threshold MMT was significantly associated with improved survival. These findings add to the known benefits of providing low-threshold MMT on reducing the harms associated with injection drug use.
BACKGROUND:Methadone maintenance therapy (MMT) is among the most effective treatment modalities available for the management of opioid use disorder. However, the effect of MMT on mortality, and optimal strategies for delivering methadone are less clear. This study sought to estimate the effect of low-threshold MMT and its association with all-cause mortality among persons who inject drugs (PWID) in a setting where methadone is widely available through primary care physicians and community pharmacies at no cost through the setting's universal medical insurance plan. METHODS: Between May, 1996 and December, 2011 data were collected as part of two prospective cohort studies of PWID in Vancouver, Canada, and were linked to the provincial vital statistics database to ascertain rates and causes of death. The association of MMT with all-cause mortality was estimated using multivariable extended Cox regression with time-dependent variables. RESULTS: Of 2335 PWID providing 15027 person-years of observation, 511 deaths were observed for a mortality rate of 3.4 (95% Confidence Interval [CI]: 3.1-3.7) deaths per 100 person-years. After adjusting for potential confounders including age and HIV seropositivity, MMT enrolment was found to be associated with lower mortality (adjusted hazard ratio [AHR]=0.73, 95% CI: 0.61-0.88). CONCLUSIONS: While observed all-cause mortality rates among PWID in this setting were high, participation in low-threshold MMT was significantly associated with improved survival. These findings add to the known benefits of providing low-threshold MMT on reducing the harms associated with injection drug use.
Authors: Anita Palepu; Mark W Tyndall; Ruth Joy; Thomas Kerr; Evan Wood; Natasha Press; Robert S Hogg; Julio S G Montaner Journal: Drug Alcohol Depend Date: 2006-03-20 Impact factor: 4.492
Authors: Hans-Ulrich Wittchen; Sabine M Apelt; Michael Soyka; Markus Gastpar; Markus Backmund; Jörg Gölz; Michael R Kraus; Felix Tretter; Martin Schäfer; Jens Siegert; Norbert Scherbaum; Jürgen Rehm; Gerhard Bühringer Journal: Drug Alcohol Depend Date: 2008-03-11 Impact factor: 4.492
Authors: James A Peterson; Robert P Schwartz; Shannon Gwin Mitchell; Heather Schacht Reisinger; Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Michael H Agar Journal: Int J Drug Policy Date: 2008-09-20
Authors: Bohdan Nosyk; Huiying Sun; Elizabeth Evans; David C Marsh; M Douglas Anglin; Yih-Ing Hser; Aslam H Anis Journal: Addiction Date: 2012-05-08 Impact factor: 6.526
Authors: N A Mohd Salleh; N Fairbairn; S Nolan; R Barrios; J Shoveller; L Richardson; M-J Milloy Journal: HIV Med Date: 2019-07-29 Impact factor: 3.180
Authors: Geoffrey R T Walton; Kanna Hayashi; Paxton Bach; Huiru Dong; Thomas Kerr; Keith Ahamad; M J Milloy; Julio Montaner; Evan Wood Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792